Tech Company Financing Transactions

CRISPR Therapeutics Funding Round

Celgene, SR One Capital Management and Abingworth invested in a $64 million Series B venture round for CRISPR Therapeutics. The round closed on 4/30/2015.

Transaction Overview

Announced On
4/30/2015
Transaction Type
Venture Equity
Amount
$64,000,000
Round
Series B
Investors

Celgene (Lead Investor)

SR One Capital Management (Lead Investor) (Simeon George)

Abingworth (Kurt von Emster)

New Enterprise Associates (Ali Behbahani)

Versant Ventures (Brad Bolzon)

Proceeds Purpose
We will be using these proceeds to advance our current and future programs toward the clinic and to expand our research and development organization in Cambridge, Massachusetts.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
610 Main St.
Cambridge, MA 02139
USA
Email Address
Overview
The mission of CRISPR Therapeutics (Nasdaq: CRSP) is to develop transformative gene-based medicines for patients with serious diseases. Our therapeutic approach is to cure diseases at the molecular level using the breakthrough gene editing technology called CRISPR-Cas9.
Profile
CRISPR Therapeutics LinkedIn Company Profile
Social Media
CRISPR Therapeutics Company Twitter Account
Company News
CRISPR Therapeutics News
Facebook
CRISPR Therapeutics on Facebook
YouTube
CRISPR Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Samarth Kulkarni
  Samarth Kulkarni LinkedIn Profile  Samarth Kulkarni Twitter Account  Samarth Kulkarni News  Samarth Kulkarni on Facebook
President
Rodger Novak
  Rodger Novak LinkedIn Profile  Rodger Novak Twitter Account  Rodger Novak News  Rodger Novak on Facebook
VP - Bus. Development
Lawrence Klein
  Lawrence Klein LinkedIn Profile  Lawrence Klein Twitter Account  Lawrence Klein News  Lawrence Klein on Facebook
VP - General Counsel
James Kasinger
  James Kasinger LinkedIn Profile  James Kasinger Twitter Account  James Kasinger News  James Kasinger on Facebook
VP - Human Resources
Megan Menner
  Megan Menner LinkedIn Profile  Megan Menner Twitter Account  Megan Menner News  Megan Menner on Facebook
VP - R & D
Tony Ho
  Tony Ho LinkedIn Profile  Tony Ho Twitter Account  Tony Ho News  Tony Ho on Facebook


 

 

Browse more venture capital transactions:

Prev: 4/30/2015: PlateJoy venture capital transaction
Next: 4/30/2015: ThreatQuotient venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to report on funding rounds that are announced publicly. All VC database entries reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary